325 0 Kommentare DARA BioSciences Supports Breastcancer.org to Increase Awareness and Raise Funds to Fight Breast Cancer

RALEIGH, NC--(Marketwired - October 24, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced it is supporting Breastcancer.org with its Sponsor level commitment to BREASTCANCER.ORG's 5th Annual ROCK the RIBBON Black & White Party. Breastcancer.org is a leading resource for breast health and breast cancer information and support.

"DARA is proud to be affiliated with Breastcancer.org and supports its mission to help women and their loved ones make sense of the complex medical and personal information about breast health and breast cancer," said Christopher G. Clement, President and CEO of DARA BioSciences.

Breastcancer.org provides an invaluable service to cancer patients and their families by publishing online the most up to date research and information regarding breast cancer, giving them important tools to help make informed decisions about their lives. The online resource brings together thousands of patients and family members via an online community.

"We are grateful for DARA's support and its unique commitment to supportive care in helping patients manage the side effects that come with frontline breast cancer therapies," said Rita Lusen, vice president of corporate partnerships and development for Breastcancer.org.

"Supporting Breastcancer.org provides DARA the opportunity to help educate breast cancer patients on the supportive care treatment options available to them," stated DARA Chief Medical Officer and Chairman of the Board David J. Drutz. M.D.

In 2013, the top searched term on breastcancer.org was tamoxifen, a selective estrogen receptor modulator, called SERM for short, which blocks the effects of estrogen in the breast tissue. Estrogen is known to play an important role in driving the growth of breast cancer cells. Tamoxifen is indicated for the treatment of metastatic breast cancer, adjuvant treatment of breast cancer, the reduction of risk of invasive breast cancer in women with ductal carcinoma in situ, and to reduce breast cancer incidence in high risk women. Currently, more than 1.9 million prescriptions of tamoxifen are written annually in the United States. Between 31 and 60 percent of patients fail to complete their prescribed course of treatment, thereby diminishing its benefits in reducing the risk of breast cancer and breast cancer recurrence.